CA2634005A1 - N-hydroxyamide derivatives possessing antibacterial activity - Google Patents
N-hydroxyamide derivatives possessing antibacterial activity Download PDFInfo
- Publication number
- CA2634005A1 CA2634005A1 CA002634005A CA2634005A CA2634005A1 CA 2634005 A1 CA2634005 A1 CA 2634005A1 CA 002634005 A CA002634005 A CA 002634005A CA 2634005 A CA2634005 A CA 2634005A CA 2634005 A1 CA2634005 A1 CA 2634005A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- group
- heteroaryl
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Abstract
Described herein are N-hydroxyamide antibacterial compounds, methods for making the compounds, pharmaceuti-cal compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical compositions.
Claims (28)
1. A compound of Formula I:
or a salt, solvate or hydrate thereof, wherein A is each ~ indicates a point of attachment;
R1 is selected from the group consisting of H, N3, NH2, NHSO2CH3, NHCOH, NHCH3, F, OCH3, and OH;
R2 is selected from the group consisting of H, OH, and NH2;
R3 is selected from the group consisting of H and CH2OCH3;
R4 is selected from the group consisting of CH2SCH3, CH2SO2CH3, SCH3, SO2CH3, and W is selected from the group consisting of S, SO, and SO2;
X1, X2, and X3 are each independently selected from the group consisting of H
and F, with the proviso that at least one of X1, X2, and X3 is F;
Y is a heteroaryl;
m is 0 or 1;
n is 1 or 2; and Ar is an optionally substituted aryl or heteroaryl;
with the proviso that the compound does not have the structure of a compound set forth in Table 1(a)-1 (d).
or a salt, solvate or hydrate thereof, wherein A is each ~ indicates a point of attachment;
R1 is selected from the group consisting of H, N3, NH2, NHSO2CH3, NHCOH, NHCH3, F, OCH3, and OH;
R2 is selected from the group consisting of H, OH, and NH2;
R3 is selected from the group consisting of H and CH2OCH3;
R4 is selected from the group consisting of CH2SCH3, CH2SO2CH3, SCH3, SO2CH3, and W is selected from the group consisting of S, SO, and SO2;
X1, X2, and X3 are each independently selected from the group consisting of H
and F, with the proviso that at least one of X1, X2, and X3 is F;
Y is a heteroaryl;
m is 0 or 1;
n is 1 or 2; and Ar is an optionally substituted aryl or heteroaryl;
with the proviso that the compound does not have the structure of a compound set forth in Table 1(a)-1 (d).
2. A compound of claim 1 having Formula I (a):
or a salt, solvate or hydrate thereof, wherein R1 is selected from the group consisting of H, N3, NH2, NHSO2CH3, NHCOH, NHCH3, F, OCH3, and OH;
R2 is selected from the group consisting of H, OH, and NH2;
R3 is selected from the group consisting of H and CH2OCH3; and Ar is an optionally substituted aryl or heteroaryl.
or a salt, solvate or hydrate thereof, wherein R1 is selected from the group consisting of H, N3, NH2, NHSO2CH3, NHCOH, NHCH3, F, OCH3, and OH;
R2 is selected from the group consisting of H, OH, and NH2;
R3 is selected from the group consisting of H and CH2OCH3; and Ar is an optionally substituted aryl or heteroaryl.
3. The compound of claim 2, wherein R1 is H, R2 is OH, and R3 is CH2OCH3.
4. The compound of claim 2 wherein R1 is selected from the group consisting of N3, NH2, NHSO2CH3, NHCOH, NHCH3, F, and OCH3; R2 is H; and R3 is H.
5. The compound of claim 4 wherein R1 is NH2.
6. The compound of claim 2 wherein R1 is OH; R2 is selected from the group consisting of OH and NH2; and R3 is H.
7. The compound of any one of claims 1-6, wherein Ar is
8. The compound of claim 1 having Formula I(b):
or a salt, solvate or hydrate thereof, wherein W is selected from the group consisting of S, SO, and SO2; and Ar is an optionally substituted aryl or heteroaryl.
or a salt, solvate or hydrate thereof, wherein W is selected from the group consisting of S, SO, and SO2; and Ar is an optionally substituted aryl or heteroaryl.
9. The compound of claim 8, wherein Ar is
10. The compound of claim 1 having Formula I (c):
or a salt, solvate or hydrate thereof, wherein W is selected from the group consisting of S, SO and SO2; and Ar is an optionally substituted aryl or heteroaryl.
or a salt, solvate or hydrate thereof, wherein W is selected from the group consisting of S, SO and SO2; and Ar is an optionally substituted aryl or heteroaryl.
11. The compound of claim 1 having Formula I (d):
or a salt, solvate or hydrate thereof, wherein W is selected from the group consisting of S, SO and SO2;
n is 1 or 2; and Ar is an optionally substituted aryl or heteroaryl.
or a salt, solvate or hydrate thereof, wherein W is selected from the group consisting of S, SO and SO2;
n is 1 or 2; and Ar is an optionally substituted aryl or heteroaryl.
12. The compound of claim 1 having Formula I (e):
or a salt, solvate or hydrate thereof, wherein Y is a heteroaryl;
m is 0 or 1; and Ar is an optionally substituted aryl or heteroaryl.
or a salt, solvate or hydrate thereof, wherein Y is a heteroaryl;
m is 0 or 1; and Ar is an optionally substituted aryl or heteroaryl.
13. The compound of claim 12, having the following structure:
14. The compound of claim 12 or 13, wherein Y is a 5-membered heteroaryl ring.
15. The compound of claim 14, wherein Y is selected from the group consisting of
16. The compound of claim 1 having Formula I (f):
or a salt, solvate or hydrate thereof, wherein R4 is selected from the group consisting of CH2SCH3, CH2SO2CH3, SCH3, SO2CH3, and ; and Ar is an optionally substituted aryl or heteroaryl.
or a salt, solvate or hydrate thereof, wherein R4 is selected from the group consisting of CH2SCH3, CH2SO2CH3, SCH3, SO2CH3, and ; and Ar is an optionally substituted aryl or heteroaryl.
17. The compound of claim 1 having Formula I (g) or a salt, solvate or hydrate thereof, wherein X1, X2, and X3 are each independently selected from the group consisting of H and F; and Ar is an optionally substituted aryl or heteroaryl.
18. The compound of claim 17, wherein X1, X2, and X3 are F.
19. The compound of claim 17, wherein X, is F, X2 is H, and X3 is H.
20. The compound of any one of claims 17-19, wherein Ar is selected from the group consisting of
21. A compound having Formula II:
or a salt, solvate or hydrate thereof, wherein Ar is an optionally substituted aryl.
or a salt, solvate or hydrate thereof, wherein Ar is an optionally substituted aryl.
22. The compound of claim 21, wherein Ar is .
23. A compound of any one of claims 1-22 having a structure set forth in Table 2, or a salt, solvate or hydrate thereof.
24. A pharmaceutical composition comprising a compound of any one of claims 1-23 and a pharmaceutically acceptable carrier, diluent or excipient.
25. A bacteriostatic and/or bactericidal method comprising:
(a) contacting a bacteria with a compound of any of claims 1-23 or a composition of claim 24.
(a) contacting a bacteria with a compound of any of claims 1-23 or a composition of claim 24.
26. The method of claim 25 wherein (a) occurs in vitro or in vivo.
27. A method of treating a bacterial infection in a mammal comprising administering an effective amount a compound of any of claims 1-23 or a composition of claim 24 to the mammal.
28. The method of claim 27 comprising preventing a bacterial infection in a mammal by administering the effective amount the compound of any of claims 1-23 or the composition of claim 24 to the mammal.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75060005P | 2005-12-15 | 2005-12-15 | |
| US60/750,600 | 2005-12-15 | ||
| PCT/IB2006/003549 WO2007069020A2 (en) | 2005-12-15 | 2006-12-04 | N-hydroxyamide derivatives possessing antibacterial activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2634005A1 true CA2634005A1 (en) | 2007-06-21 |
| CA2634005C CA2634005C (en) | 2012-01-03 |
Family
ID=38163279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2634005A Expired - Fee Related CA2634005C (en) | 2005-12-15 | 2006-12-04 | N-hydroxyamide derivatives possessing antibacterial activity |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8088804B2 (en) |
| EP (2) | EP2338878A3 (en) |
| JP (1) | JP2009520695A (en) |
| CA (1) | CA2634005C (en) |
| WO (1) | WO2007069020A2 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004007444A2 (en) | 2002-07-11 | 2004-01-22 | Vicuron Pharmaceuticals, Inc. | N-hydroxyamide derivatives possessing antibacterial activity |
| EP2662353A3 (en) | 2007-06-12 | 2014-04-02 | Achaogen, Inc. | Antibacterial agents |
| US20110015158A1 (en) | 2007-12-11 | 2011-01-20 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
| CA2733390A1 (en) * | 2008-08-01 | 2010-02-04 | Bioxiness Pharmaceuticals, Inc. | Methionine analogs and methods of using same |
| US8722686B2 (en) | 2008-09-19 | 2014-05-13 | Pfizer Inc. | Hydroxamic acid derivatives useful as antibacterial agents |
| JP5746864B2 (en) * | 2008-11-19 | 2015-07-08 | ポーラ化成工業株式会社 | Wrinkle improving agent |
| US8853258B2 (en) | 2009-10-13 | 2014-10-07 | Pfizer Inc. | C-linked hydroxamic acid derivatives useful as antibacterial agents |
| WO2011073845A1 (en) | 2009-12-16 | 2011-06-23 | Pfizer Inc. | N-linked hydroxamic acid derivatives useful as antibacterial agents |
| SG184958A1 (en) | 2010-04-20 | 2012-11-29 | Taisho Pharmaceutical Co Ltd | Novel hydroxamic acid derivative |
| UA107423C2 (en) * | 2011-03-07 | 2014-12-25 | Pfizer | Fluoro-pyridinone derivatives useful as antibacterial agents |
| DK2694488T3 (en) | 2011-04-08 | 2014-12-15 | Pfizer | Isoxazole derivatives useful as antibacterial SUBSTANCES |
| KR20130140164A (en) | 2011-04-08 | 2013-12-23 | 화이자 인코포레이티드 | Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
| JP6006609B2 (en) * | 2011-10-19 | 2016-10-12 | 大正製薬株式会社 | Pharmaceuticals containing novel hydroxamic acid derivatives |
| EP2847168A1 (en) | 2012-05-10 | 2015-03-18 | Achaogen, Inc. | Antibacterial agents |
| RS58930B1 (en) | 2013-03-15 | 2019-08-30 | Fujifilm Toyama Chemical Co Ltd | Novel hydroxamic acid derivative or salt thereof |
| EP2883876A1 (en) | 2013-12-16 | 2015-06-17 | Actelion Pharmaceuticals Ltd. | Stereoselective synthesis of substituted pyrrolidines |
| MX2017002967A (en) | 2014-09-12 | 2017-05-30 | Toyama Chemical Co Ltd | Novel pharmaceutical composition containing hydroxamic acid derivative or salt thereof. |
| US10123990B2 (en) | 2014-09-12 | 2018-11-13 | Toyama Chemical Co., Ltd. | Method for using novel hydroxamic acid derivative and antibacterial substance in combination |
| CN108569991A (en) * | 2018-05-31 | 2018-09-25 | 常州制药厂有限公司 | A kind of preparation method of anti-hepatitis C virus key intermediate of medicament |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4077998A (en) * | 1975-10-28 | 1978-03-07 | Morton-Norwich Products, Inc. | Phthaloyl amino acid hydroxamic acids |
| CA2227237C (en) * | 1995-07-26 | 2005-12-13 | Pfizer Inc. | N-(aroyl)glycine hydroxamic acid derivatives and related compounds |
| WO1997017070A1 (en) * | 1995-11-06 | 1997-05-15 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| US6693123B2 (en) | 1995-11-06 | 2004-02-17 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| US5925659A (en) | 1996-05-07 | 1999-07-20 | Merck & Co., Inc. | Antibacterial agents |
| NZ503945A (en) | 1997-07-31 | 2002-11-26 | Procter & Gamble | Metalloprotease-inhibiting amide derivatives |
| US6784173B2 (en) * | 2001-06-15 | 2004-08-31 | Hoffmann-La Roche Inc. | Aromatic dicarboxylic acid derivatives |
| WO2004007444A2 (en) | 2002-07-11 | 2004-01-22 | Vicuron Pharmaceuticals, Inc. | N-hydroxyamide derivatives possessing antibacterial activity |
| CN102267924A (en) * | 2003-01-08 | 2011-12-07 | 诺华疫苗和诊断公司 | Antibacterial agents |
| US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| DE10348023A1 (en) * | 2003-10-15 | 2005-05-19 | Imtm Gmbh | New alanyl aminopeptidase inhibitors for the functional manipulation of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases |
| JP2008508348A (en) * | 2004-08-02 | 2008-03-21 | ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ | Compounds for inhibiting copper-containing amine oxidase and uses thereof |
| WO2006040646A1 (en) * | 2004-10-14 | 2006-04-20 | Pfizer, Inc. | Benzimidazole or indole amides as inhibitors of pin1 |
| WO2007017728A2 (en) | 2005-08-05 | 2007-02-15 | Orchid Research Laboratories Limited | Novel heterocyclic compounds |
-
2006
- 2006-12-04 CA CA2634005A patent/CA2634005C/en not_active Expired - Fee Related
- 2006-12-04 EP EP11151502A patent/EP2338878A3/en not_active Withdrawn
- 2006-12-04 JP JP2008545125A patent/JP2009520695A/en active Pending
- 2006-12-04 WO PCT/IB2006/003549 patent/WO2007069020A2/en active Application Filing
- 2006-12-04 EP EP06821047A patent/EP1963262A2/en not_active Withdrawn
- 2006-12-04 US US12/097,307 patent/US8088804B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20100022605A1 (en) | 2010-01-28 |
| EP2338878A3 (en) | 2011-11-16 |
| JP2009520695A (en) | 2009-05-28 |
| WO2007069020A3 (en) | 2008-06-19 |
| EP1963262A2 (en) | 2008-09-03 |
| CA2634005C (en) | 2012-01-03 |
| EP2338878A2 (en) | 2011-06-29 |
| WO2007069020A2 (en) | 2007-06-21 |
| US8088804B2 (en) | 2012-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2634005A1 (en) | N-hydroxyamide derivatives possessing antibacterial activity | |
| LUC00155I1 (en) | ||
| HK1111999A1 (en) | Spiroketal derivative and use thereof as diabetic medicine | |
| SE9904108D0 (en) | New compounds | |
| NO20085240L (en) | C-phenyl 1-thioglucitol | |
| JP2009520695A5 (en) | ||
| MY137039A (en) | Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof | |
| EP1679309A4 (en) | Antistress drug and medical use thereof | |
| WO2008108380A3 (en) | Pyrrole compounds | |
| CO5280078A1 (en) | COMPOUNDS | |
| EP2075011A3 (en) | Prodrugs containing bio-cleavable disulfide linkers | |
| WO2007138110A3 (en) | Compounds that interact with ion channels, in particular with ion channels from the kv family | |
| WO2007099548A3 (en) | Novel 11 beta - hydroxyandrosta-4-ene-3-ones | |
| WO2010030704A3 (en) | Antibacterial aminoglycoside analogs | |
| PL1961734T3 (en) | Amine compound and use thereof for medical purposes | |
| WO2008140099A1 (en) | Tetrazoyloxime derivative and plant disease control agent | |
| EA200701035A1 (en) | SUBSTITUTED N-SULPHONYLAMINOBENZIL-2-PHENOXYACETAMIDE COMPOUNDS | |
| WO2004071388A3 (en) | Medicinal compounds | |
| WO2007017728A3 (en) | Novel heterocyclic compounds | |
| EP1634874A4 (en) | Imidazolidine derivative | |
| CA2336412A1 (en) | Medicament for treatment of diabetes | |
| NO20040881L (en) | Oral antidiabetic agents. | |
| EA200600694A1 (en) | DISULPHID, SULPHIDE, SULPHOXIDE AND SULPHONE DERIVATIVES OF CYCLIC SUGARS AND THEIR APPLICATION | |
| MY135954A (en) | Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid | |
| NO20063111L (en) | Process for the preparation of thiazole pyrimidines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20141204 |